Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach
- PMID: 25707517
- DOI: 10.3109/0886022X.2015.1010442
Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach
Abstract
The aim of this study was to develop a population pharmacokinetic (PK) model for clearance of mycophenolic acid (MPA) in adult renal transplant recipients, to quantify the PK parameters and the influence of covariates on the MPA pharmacokinetic parameters. Parameters associated with plasma concentrations of MPA at steady-state were analyzed in 70 renal transplant recipients (mean age 42.97 years; mean total body weight 75.33 kg) using nonlinear mixed-effect modeling (NONMEM). Characteristics of patients screened for influence on the pharmacokinetic parameters were gender, age, body weight, time after transplantation, whether the patient was diagnosed as having diabetes mellitus, organ source (living or deceased donor), biochemical parameters and co-therapy (tacrolimus, cyclosporine, prednisolone, omeprazole, bisoprolol, carvedilol, nifedipine). A validation set of 25 renal transplant recipients was used to estimate the predictive performance of population pharmacokinetic model. Typical mean value of MPA oral clearance, estimated by base model (without covariates) was 0.741 L h(-1). During population modeling, the full model showed that clearance of the MPA was significantly influenced by age, total daily dose of MPA, creatinine clearance, albumin level, status and gender of a donor, and the nifedipine and tacrolimus co-therapy. In the final model, clearance of MPA was reported to be significantly influenced by age, total daily dose of MPA and thenifedipine co-therapy. The derived model describes adequately MPA clearance in terms of characteristics of our patients, offering basis for individual pharmacotherapy approach.
Keywords: Mycophenolic acid; nonlinear mixed effects model (NONM); population pharmacokinetics; renal transplantation.
Similar articles
-
A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation.J Clin Pharmacol. 2012 Dec;52(12):1833-43. doi: 10.1177/0091270011423661. Epub 2011 Dec 29. J Clin Pharmacol. 2012. PMID: 22207766 Clinical Trial.
-
Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation.Eur J Clin Pharmacol. 2005 Aug;61(7):507-16. doi: 10.1007/s00228-005-0927-4. Epub 2005 Jul 28. Eur J Clin Pharmacol. 2005. PMID: 16049701
-
Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction.Ther Drug Monit. 2010 Aug;32(4):427-32. doi: 10.1097/FTD.0b013e3181e6b54d. Ther Drug Monit. 2010. PMID: 20592648
-
Population Pharmacokinetics of Mycophenolic Acid: An Update.Clin Pharmacokinet. 2018 May;57(5):547-558. doi: 10.1007/s40262-017-0593-6. Clin Pharmacokinet. 2018. PMID: 28861847
-
Recent lessons learned from population pharmacokinetic studies of mycophenolic acid: physiological, genomic, and drug interactions leading to the prediction of drug effects.Expert Opin Drug Metab Toxicol. 2021 Dec;17(12):1369-1406. doi: 10.1080/17425255.2021.2027906. Epub 2022 Jan 24. Expert Opin Drug Metab Toxicol. 2021. PMID: 35000505 Review.
Cited by
-
Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation-a prospective, observational study.Arthritis Res Ther. 2020 Oct 6;22(1):230. doi: 10.1186/s13075-020-02323-8. Arthritis Res Ther. 2020. PMID: 33023643 Free PMC article.
-
Published population pharmacokinetic models of mycophenolate sodium: a systematic review and external evaluation in a Chinese sample of renal transplant recipients.Front Pharmacol. 2025 Aug 18;16:1632568. doi: 10.3389/fphar.2025.1632568. eCollection 2025. Front Pharmacol. 2025. PMID: 40900829 Free PMC article.
-
Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Patients: A Comparison of the Early and Stable Posttransplant Stages.Front Pharmacol. 2022 May 9;13:859351. doi: 10.3389/fphar.2022.859351. eCollection 2022. Front Pharmacol. 2022. PMID: 35614937 Free PMC article.
-
Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients.Clin Pharmacokinet. 2019 Nov;58(11):1483-1495. doi: 10.1007/s40262-019-00771-3. Clin Pharmacokinet. 2019. PMID: 31055791
-
Clinical Evidence on the Purported Pharmacokinetic Interactions between Corticosteroids and Mycophenolic Acid.Clin Pharmacokinet. 2023 Feb;62(2):157-207. doi: 10.1007/s40262-023-01212-y. Epub 2023 Feb 27. Clin Pharmacokinet. 2023. PMID: 36848031
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical